G

Gentian Diagnostics ASA
OSE:GENT

Watchlist Manager
Gentian Diagnostics ASA
OSE:GENT
Watchlist
Price: 40.8 NOK -0.49% Market Closed
Market Cap: 629.2m NOK
Have any thoughts about
Gentian Diagnostics ASA?
Write Note

Wall Street
Price Targets

GENT Price Targets Summary
Gentian Diagnostics ASA

Wall Street analysts forecast GENT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GENT is 68.34 NOK with a low forecast of 67.67 NOK and a high forecast of 70.35 NOK.

Lowest
Price Target
67.67 NOK
66% Upside
Average
Price Target
68.34 NOK
68% Upside
Highest
Price Target
70.35 NOK
72% Upside
Gentian Diagnostics ASA Competitors:
Price Targets
AP4
Riverstone Holdings Ltd
12% Upside
6491
Pegavision Corp
27% Upside
603658
Autobio Diagnostics Co Ltd
34% Upside
ALC
Alcon AG
19% Upside
4549
Eiken Chemical Co Ltd
7% Upside
LNTH
Lantheus Holdings Inc
51% Upside

Revenue
Forecast

Revenue Estimate
Gentian Diagnostics ASA

For the last 7 years the compound annual growth rate for Gentian Diagnostics ASA's revenue is 28%. The projected CAGR for the next 2 years is 29%.

28%
Past Growth
29%
Estimated Growth
Estimates Accuracy
-15%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Gentian Diagnostics ASA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Net Income
Forecast

Net Income Estimate
Gentian Diagnostics ASA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GENT's stock price target?
Price Target
68.34 NOK

According to Wall Street analysts, the average 1-year price target for GENT is 68.34 NOK with a low forecast of 67.67 NOK and a high forecast of 70.35 NOK.

What is Gentian Diagnostics ASA's Revenue forecast?
Projected CAGR
29%

For the last 7 years the compound annual growth rate for Gentian Diagnostics ASA's revenue is 28%. The projected CAGR for the next 2 years is 29%.

Back to Top